DABIGATRAN AND MYOCARDIAL INFARCTION, DRUG OR CLASS EFFECT. META-ANALYSIS OF RANDOMIZED TRIALS WITH ORAL DIRECT THROMBIN INHIBITORS
| Autor: | Eric Rome, Ramin Artang, Humberto Vidaillet |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject Warfarin Atrial fibrillation medicine.disease Dabigatran law.invention Randomized controlled trial law Internal medicine Meta-analysis medicine Cardiology cardiovascular diseases Myocardial infarction business Cardiology and Cardiovascular Medicine medicine.drug media_common Discovery and development of direct thrombin inhibitors |
| Zdroj: | Journal of the American College of Cardiology. 59(13) |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(12)60572-5 |
| Popis: | The recent trial on dabigatran versus warfarin in Atrial Fibrillation (RELY) demonstrated dabigatran 150 mg twice daily was associated with small but statistically significant increased number of Myocardial Infarction (MI) as compared to warfarin. The purpose of this study was to investigate whether |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|